Article

Developing High-Affinity Decoy Receptor Optimized for Multiple Myeloma and Diffuse Large B Cell Lymphoma Treatment

2021-05-04

Abstract excerpt

<h4>ABSTRACT</h4> Recent T Cell therapies have been effective in the treatment of hematological cancers. However, immunotoxicity and treatment relapse pose significant clinical challenges. Here, we revealed distinctive requirement for neutralizing TNF receptor ligands APRIL and BAFF in MM and DLBCL. Furthermore, we investigated the use of BCMA decoy receptor (sBCMA-Fc) as a therapeutic inhibitor of ARPIL and BAFF...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ccdee202-3ba4-5782-bdb2-ab38263d7076
DOI: 10.1101/2021.05.03.442500

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Developing High-Affinity Decoy Receptor Optimized for Multiple Myeloma and Diffuse Large B Cell Lymphoma TreatmentDOI 10.1101/2021.05.03.442500Read

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity Read

Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF.Semantic proximity Read

Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalizationSemantic proximity Read

Rapid BCMA downmodulation on myeloma cells upon CAR T cell contact is mediated by trogocytosis and BCMA internalizationSemantic proximity Read

Combinatorial T cell engineering eliminates on-target off-tumor toxicity of CD229 CAR T cells while maintaining anti-tumor activitySemantic proximity Read

Rational engineering of sdAb-based CAR T cells targeting BCMA enhances antitumor efficacy and persistence in Multiple MyelomaSemantic proximity Read

Novel SLAMF1-derived peptide induces apoptosis in multiple myeloma cells by targeting IRF4 transcription factor for degradationSemantic proximity Read

Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamilySemantic proximity Read

Engineering an APRIL-specific B cell maturation antigen.Semantic proximity Read

BCMA/CD19 dual-targeting with FasTCAR: AZD0120 demonstrates potent preclinical efficacy in multiple myelomaSemantic proximity Read

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaSemantic proximity Read

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple MyelomaSemantic proximity Read